{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:04:24Z","timestamp":1789016664876,"version":"build-2803163510"},"reference-count":534,"publisher":"Harborside Press, LLC","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p content-type=\"flushleft\">\n                    Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a\n                    <jats:italic>BCR-ABL1<\/jats:italic>\n                    fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2020.0047","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T15:19:31Z","timestamp":1601997571000},"page":"1385-1415","source":"Crossref","is-referenced-by-count":219,"title":["Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology"],"prefix":"10.6004","volume":"18","author":[{"given":"Michael W.","family":"Deininger","sequence":"first","affiliation":[{"name":"1Huntsman Cancer Institute at the University of Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"Shah","sequence":"additional","affiliation":[{"name":"2UCSF Helen Diller Family Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Altman","sequence":"additional","affiliation":[{"name":"3Robert H. Lurie Comprehensive Cancer Center of Northwestern University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellin","family":"Berman","sequence":"additional","affiliation":[{"name":"4Memorial Sloan Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[{"name":"5O'Neal Comprehensive Cancer Center at UAB;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"6The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"7Dana-Farber\/Brigham and Women\u2019s Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[{"name":"8Stanford Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Hobbs","sequence":"additional","affiliation":[{"name":"9Massachusetts General Hospital Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Maness","sequence":"additional","affiliation":[{"name":"10Fred and Pamela Buffett Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Mead","sequence":"additional","affiliation":[{"name":"11UCLA Jonsson Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leland","family":"Metheny","sequence":"additional","affiliation":[{"name":"12Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Mohan","sequence":"additional","affiliation":[{"name":"13Vanderbilt-Ingram Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph O.","family":"Moore","sequence":"additional","affiliation":[{"name":"14Duke Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Naqvi","sequence":"additional","affiliation":[{"name":"15The University of Texas MD Anderson Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Oehler","sequence":"additional","affiliation":[{"name":"16Fred Hutchinson Cancer Research Center\/Seattle Cancer Care Alliance;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnel M.","family":"Pallera","sequence":"additional","affiliation":[{"name":"17St. Jude Children's Research Hospital\/The University of Tennessee Health Science Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal","family":"Patnaik","sequence":"additional","affiliation":[{"name":"18Mayo Clinic Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Pratz","sequence":"additional","affiliation":[{"name":"19Abramson Cancer Center at the University of Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iskra","family":"Pusic","sequence":"additional","affiliation":[{"name":"20Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal G.","family":"Rose","sequence":"additional","affiliation":[{"name":"21Yale Cancer Center\/Smilow Cancer Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Douglas","family":"Smith","sequence":"additional","affiliation":[{"name":"22The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Snyder","sequence":"additional","affiliation":[{"name":"23City of Hope National Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra L.","family":"Sweet","sequence":"additional","affiliation":[{"name":"24Moffitt Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[{"name":"25University of Michigan Rogel Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Thompson","sequence":"additional","affiliation":[{"name":"26Roswell Park Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Yang","sequence":"additional","affiliation":[{"name":"27University of Wisconsin Carbone Cancer Center; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina M.","family":"Gregory","sequence":"additional","affiliation":[{"name":"28National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Sundar","sequence":"additional","affiliation":[{"name":"28National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref1851","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"M\u00fcller","year":"2009","journal-title":"Blood"},{"key":"ref4181","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk Res"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1658-3876(09)50026-X","article-title":"Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia","volume":"2","author":"Aleem","year":"2009","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"ref2691","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1038\/bcj.2014.60","article-title":"A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"4","author":"Seymour","year":"2014","journal-title":"Blood Cancer J"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"key":"ref2971","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1002\/cncr.10490","article-title":"Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR\/ABL mRNA and undetectable BCR\/ABL protein may predict an indolent course","volume":"94","author":"Verstovsek","year":"2002","journal-title":"Cancer"},{"key":"ref3821","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1185\/03007995.2014.904281","article-title":"Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase","volume":"30","author":"Gu\u00e9rin","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"ref2131","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"ref4001","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1200\/JCO.2010.33.9176","article-title":"Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy","volume":"29","author":"Kantarjian","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref1531","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s00277-018-3413-7","article-title":"Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?","volume":"97","author":"Osorio","year":"2018","journal-title":"Ann Hematol"},{"key":"ref4041","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3324\/haematol.2017.171249","article-title":"Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I\/II study","volume":"103","author":"Gambacorti-Passerini","year":"2018","journal-title":"Haematologica"},{"key":"ref1891","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"key":"ref1661","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","article-title":"Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties","volume":"158","author":"Hegedus","year":"2009","journal-title":"Br J Pharmacol"},{"key":"ref2841","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood.V86.8.3118.3118","article-title":"Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals","volume":"86","author":"Biernaux","year":"1995","journal-title":"Blood"},{"key":"ref4941","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3389\/fonc.2020.00883","article-title":"Current strategies and future directions to achieve deep molecular response and treatment-free remission in chronic myeloid leukemia","volume":"10","author":"Annunziata","year":"2020","journal-title":"Front Oncol"},{"key":"ref5181","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ijgo.2003.11.014","article-title":"Pregnancy in chronic myeloid leukemia patients treated with alpha interferon","volume":"85","author":"Al Bahar","year":"2004","journal-title":"Int J Gynaecol Obstet"},{"key":"ref2101","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study","volume":"90","author":"Mori","year":"2015","journal-title":"Am J Hematol"},{"key":"ref3921","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00277-013-1816-z","article-title":"Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy","volume":"92","author":"Wang","year":"2013","journal-title":"Ann Hematol"},{"key":"ref1541","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"ref2021","first-page":"235","article-title":"The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia","volume":"91","author":"Wang","year":"2006","journal-title":"Haematologica"},{"key":"ref3731","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1080\/10428190600783551","article-title":"Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR\/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia","volume":"47","author":"Landstrom","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"ref4461","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-019-0815-5","article-title":"Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper","volume":"12","author":"Soverini","year":"2019","journal-title":"J Hematol Oncol"},{"key":"ref5351","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bjh.16381","article-title":"Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)","volume":"189","author":"Do","year":"2020","journal-title":"Br J Haematol"},{"key":"ref4551","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2008-04-149948","article-title":"Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"ref2481","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1532\/IJH97.A20610","article-title":"Pregnancies in patients with chronic myeloid leukemia in the era of imatinib","volume":"84","author":"Koh","year":"2006","journal-title":"Int J Hematol"},{"key":"ref3591","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/cncr.11812","article-title":"Imatinib mesylate causes hypopigmentation in the skin","volume":"98","author":"Tsao","year":"2003","journal-title":"Cancer"},{"key":"ref2411","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1600-0609.1996.tb00497.x","article-title":"Two cases of CML treated with alpha-interferon during second and third trimester of pregnancy with analysis of the drug in the new-born immediately postpartum","volume":"57","author":"Haggstrom","year":"1996","journal-title":"Eur J Haematol"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/cncr.11812","article-title":"Imatinib mesylate causes hypopigmentation in the skin","volume":"98","author":"Tsao","year":"2003","journal-title":"Cancer"},{"key":"ref5331","doi-asserted-by":"crossref","first-page":"e2014028","DOI":"10.4084\/mjhid.2014.028","article-title":"Tyrosine kinase inhibitors and pregnancy","volume":"6","author":"Abruzzese","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref1491","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","article-title":"The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up","volume":"114","author":"Garg","year":"2009","journal-title":"Blood"},{"key":"ref5281","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/GCO.0b013e3282f10e33","article-title":"The use of low-molecular-weight heparins in pregnancy--how safe are they?","volume":"19","author":"Deruelle","year":"2007","journal-title":"Curr Opin Obstet Gynecol"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1002\/cncr.24432","article-title":"Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure","volume":"115","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer"},{"key":"ref4111","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1016\/S2352-3026(16)30167-3","article-title":"Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial","volume":"3","author":"Cortes","year":"2016","journal-title":"Lancet Haematol"},{"key":"ref4701","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","article-title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","volume":"33","author":"Branford","year":"2019","journal-title":"Leukemia"},{"key":"ref2161","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment","volume":"18","author":"Okada","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref2891","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ajh.24774","article-title":"The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am J Hematol"},{"key":"ref2521","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.3324\/haematol.2015.139691","article-title":"Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series","volume":"101","author":"Beauverd","year":"2016","journal-title":"Haematologica"},{"key":"ref2911","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00432-016-2321-2","article-title":"No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib","volume":"143","author":"Pfirrmann","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood.V86.6.2343.bloodjournal8662343","article-title":"Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment","volume":"86","author":"Seong","year":"1995","journal-title":"Blood"},{"key":"ref5131","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/(SICI)1096-8652(199809)59:1<101::AID-AJH23>3.0.CO;2-D","article-title":"Interferon-alpha therapy for chronic myelogenous leukemia during pregnancy","volume":"59","author":"Kuroiwa","year":"1998","journal-title":"Am J Hematol"},{"key":"ref5231","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.3324\/haematol.2015.139691","article-title":"Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series","volume":"101","author":"Beauverd","year":"2016","journal-title":"Haematologica"},{"key":"ref4661","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.clml.2015.02.035","article-title":"Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia","volume":"15","author":"Soverini","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref4711","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/bloodadvances.2019000943","article-title":"Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia","volume":"4","author":"Adnan Awad","year":"2020","journal-title":"Blood Adv"},{"key":"ref4481","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)","volume":"20","author":"Nicolini","year":"2006","journal-title":"Leukemia"},{"key":"ref5031","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"key":"ref2301","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/1078155213500686","article-title":"Effect of imatinib on male reproductive hormones in BCR-ABL positive CML patients: A preliminary report","volume":"20","author":"Ghalaut","year":"2014","journal-title":"J Oncol Pharm Pract"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cancergen.2019.07.008","article-title":"Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors","volume":"238","author":"Ni","year":"2019","journal-title":"Cancer Genet"},{"key":"ref2701","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.leukres.2018.10.002","article-title":"A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease","volume":"74","author":"Sweet","year":"2018","journal-title":"Leuk Res"},{"key":"ref2741","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0950-3536(97)80003-0","article-title":"BCR-ABL gene variants","volume":"10","author":"Melo","year":"1997","journal-title":"Baillieres Clin Haematol"},{"key":"ref3771","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.5858\/arpa.2013-0584-OA","article-title":"Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study","volume":"138","author":"Akard","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"ref2231","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3389\/fonc.2020.00883","article-title":"Current strategies and future directions to achieve deep molecular response and treatment-free remission in chronic myeloid leukemia","volume":"10","author":"Annunziata","year":"2020","journal-title":"Front Oncol"},{"key":"ref1291","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1200\/JCO.2010.33.9176","article-title":"Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy","volume":"29","author":"Kantarjian","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref2381","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2010-04-280206","article-title":"Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response","volume":"116","author":"Kuwabara","year":"2010","journal-title":"Blood"},{"key":"ref2981","first-page":"458716","article-title":"Chronic myeloid leukemia with e19a2 BCR-ABL1 transcripts and marked thrombocytosis: the role of molecular monitoring","volume":"2012","author":"Langabeer","year":"2012","journal-title":"Case Rep Hematol"},{"key":"ref4871","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment","volume":"18","author":"Okada","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref1481","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40261-018-0623-7","article-title":"Low-dose ponatinib in intolerant chronic myeloid leukemia patients: a safe and effective option","volume":"38","author":"Iurlo","year":"2018","journal-title":"Clin Drug Investig"},{"key":"ref2431","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/(SICI)1099-1069(199609)14:3<119::AID-HON576>3.0.CO;2-Q","article-title":"Alpha-interferon and pregnancy in a patient with CML","volume":"14","author":"Lipton","year":"1996","journal-title":"Hematol Oncol"},{"key":"ref3751","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/cncr.25678","article-title":"Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond","volume":"117","author":"Lima","year":"2011","journal-title":"Cancer"},{"key":"ref4511","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"key":"ref3611","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12185-019-02596-z","article-title":"Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia","volume":"109","author":"Sakurai","year":"2019","journal-title":"Int J Hematol"},{"key":"ref2371","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref1981","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"key":"ref2671","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/cncr.23006","article-title":"Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"key":"ref5371","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/cncr.22901","article-title":"Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"key":"ref1951","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.clml.2015.02.035","article-title":"Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia","volume":"15","author":"Soverini","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref2221","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12943-018-0805-1","article-title":"Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia","volume":"17","author":"Massimino","year":"2018","journal-title":"Mol Cancer"},{"key":"ref4831","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1038\/s41375-018-0264-0","article-title":"Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells","volume":"32","author":"Ross","year":"2018","journal-title":"Leukemia"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2003-02-0371","article-title":"Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate","volume":"103","author":"O\u2019Dwyer","year":"2004","journal-title":"Blood"},{"key":"ref1521","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.clml.2018.12.004","article-title":"Cardiovascular risk and cardiovascular events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"19","author":"Assun\u00e7\u00e3o","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref3201","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/cncr.22936","article-title":"The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells","volume":"110","author":"Deininger","year":"2007","journal-title":"Cancer"},{"key":"ref5321","article-title":"Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and literature review","author":"Chelysheva","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref2711","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"ref1791","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1080\/10428194.2019.1636984","article-title":"Occurrence of chromosomal abnormalities in Philadelphia chromosome-negative metaphases in patients with chronic-phase chronic myeloid leukemia undergoing TKI treatments","volume":"60","author":"Sheng","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref1161","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"key":"ref3881","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","volume":"28","author":"Hanfstein","year":"2014","journal-title":"Leukemia"},{"key":"ref5191","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1532\/IJH97.A20610","article-title":"Pregnancies in patients with chronic myeloid leukemia in the era of imatinib","volume":"84","author":"Koh","year":"2006","journal-title":"Int J Hematol"},{"key":"ref341","article-title":"Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia [published online June 6, 2020]","author":"Pagani","journal-title":"Leuk Lymphoma"},{"key":"ref3831","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"ref4921","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"ref4291","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1185\/03007995.2011.649849","article-title":"Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia","volume":"28","author":"Yood","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"ref4631","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"Soverini","year":"2014","journal-title":"Leuk Res"},{"key":"ref2011","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3324\/haematol.11064","article-title":"Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure","volume":"92","author":"Fabarius","year":"2007","journal-title":"Haematologica"},{"key":"ref5241","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jjco\/hyh038","article-title":"Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature","volume":"34","author":"Ali","year":"2004","journal-title":"Jpn J Clin Oncol"},{"key":"ref4781","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref3421","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref4841","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"ref1321","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"ref4791","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/j.ejca.2013.06.018","article-title":"Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)","volume":"49","author":"Thielen","year":"2013","journal-title":"Eur J Cancer"},{"key":"ref3171","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0301-472X(03)00176-0","article-title":"The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"31","author":"Feldman","year":"2003","journal-title":"Exp Hematol"},{"key":"ref4901","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","article-title":"Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial","volume":"7","author":"Kimura","year":"2020","journal-title":"Lancet Haematol"},{"key":"ref4221","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ajh.23408","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors","volume":"88","author":"Cortes","year":"2013","journal-title":"Am J Hematol"},{"key":"ref4441","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2009.166","article-title":"Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters","volume":"23","author":"Davies","year":"2009","journal-title":"Leukemia"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3324\/haematol.2013.090282","article-title":"Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months","volume":"98","author":"Nazha","year":"2013","journal-title":"Haematologica"},{"key":"ref4491","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref1341","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"ref5081","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"969","DOI":"10.5858\/arpa.2014-0522-LE","article-title":"Standardized molecular monitoring for variant BCR-ABL1 transcripts in chronic myeloid leukemia","volume":"139","author":"Langabeer","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"ref4201","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","article-title":"The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up","volume":"114","author":"Garg","year":"2009","journal-title":"Blood"},{"key":"ref1271","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/s41375-018-0055-7","article-title":"Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV","volume":"32","author":"Saussele","year":"2018","journal-title":"Leukemia"},{"key":"ref1391","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","article-title":"TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets","volume":"125","author":"Yeung","year":"2015","journal-title":"Blood"},{"key":"ref4191","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40261-018-0623-7","article-title":"Low-dose ponatinib in intolerant chronic myeloid leukemia patients: a safe and effective option","volume":"38","author":"Iurlo","year":"2018","journal-title":"Clin Drug Investig"},{"key":"ref4331","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00277-018-3295-8","article-title":"Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study","volume":"97","author":"Kim","year":"2018","journal-title":"Ann Hematol"},{"key":"ref1921","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"Soverini","year":"2014","journal-title":"Leuk Res"},{"key":"ref3891","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.23923","article-title":"Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am J Hematol"},{"key":"ref5291","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.jp.7211665","article-title":"Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk","volume":"27","author":"Russell","year":"2007","journal-title":"J Perinatol"},{"key":"ref4751","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2009.07646.x","article-title":"Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?","volume":"145","author":"Marin","year":"2009","journal-title":"Br J Haematol"},{"key":"ref5011","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/1078155213500686","article-title":"Effect of imatinib on male reproductive hormones in BCR-ABL positive CML patients: A preliminary report","volume":"20","author":"Ghalaut","year":"2014","journal-title":"J Oncol Pharm Pract"},{"key":"ref1741","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"ref2061","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref1361","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2003-06-2042","article-title":"Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses","volume":"102","author":"Marin","year":"2003","journal-title":"Blood"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijcard.2019.04.051","article-title":"Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention","volume":"288","author":"Caocci","year":"2019","journal-title":"Int J Cardiol"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.23923","article-title":"Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am J Hematol"},{"key":"ref1911","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2015-08-660977","article-title":"Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients","volume":"127","author":"Deininger","year":"2016","journal-title":"Blood"},{"key":"ref2321","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"key":"ref5061","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/s41598-019-39134-0","article-title":"Imatinib treatments have long-term impact on placentation and embryo survival","volume":"9","author":"Salem","year":"2019","journal-title":"Sci Rep"},{"key":"ref5381","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/cncr.23006","article-title":"Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"key":"ref3241","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/j.leukres.2009.05.010","article-title":"Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy","volume":"33","author":"Baldazzi","year":"2009","journal-title":"Leuk Res"},{"key":"ref2421","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/(SICI)1096-8652(199809)59:1<101::AID-AJH23>3.0.CO;2-D","article-title":"Interferon-alpha therapy for chronic myelogenous leukemia during pregnancy","volume":"59","author":"Kuroiwa","year":"1998","journal-title":"Am J Hematol"},{"key":"ref4561","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"M\u00fcller","year":"2009","journal-title":"Blood"},{"key":"ref2261","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"key":"ref5111","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.21873\/invivo.11641","article-title":"Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib","volume":"33","author":"Stella","year":"2019","journal-title":"In Vivo"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood.V91.9.3357","article-title":"Highly sensitive fluorescence in situ hybridization method to detect double BCR\/ABL fusion and monitor response to therapy in chronic myeloid leukemia","volume":"91","author":"Dewald","year":"1998","journal-title":"Blood"},{"key":"ref3011","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/asheducation-2018.1.168","article-title":"Molecular monitoring in CML: how deep? How often? How should it influence therapy?","volume":"2018","author":"Shanmuganathan","year":"2018","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref4771","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4137\/CMO.S6413","article-title":"Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy","volume":"4","author":"Serpa","year":"2010","journal-title":"Clin Med Insights Oncol"},{"key":"ref5261","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/trf.14448","article-title":"Management of chronic myeloid leukemia in the setting of pregnancy: when is leukocytapheresis appropriate? A case report and review of the literature","volume":"58","author":"Staley","year":"2018","journal-title":"Transfusion"},{"key":"ref3961","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.2011.36.0693","article-title":"Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?","volume":"29","author":"Jabbour","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-01-070045","article-title":"Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"110","author":"Jabbour","year":"2007","journal-title":"Blood"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"ref2641","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bjh.16381","article-title":"Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)","volume":"189","author":"Do","year":"2020","journal-title":"Br J Haematol"},{"key":"ref3131","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","article-title":"Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML","volume":"94","author":"Fabarius","year":"2015","journal-title":"Ann Hematol"},{"key":"ref2751","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"ref2801","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood.V86.6.2343.bloodjournal8662343","article-title":"Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment","volume":"86","author":"Seong","year":"1995","journal-title":"Blood"},{"key":"ref1331","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3324\/haematol.2017.171249","article-title":"Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I\/II study","volume":"103","author":"Gambacorti-Passerini","year":"2018","journal-title":"Haematologica"},{"key":"ref3651","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.clml.2018.12.004","article-title":"Cardiovascular risk and cardiovascular events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"19","author":"Assun\u00e7\u00e3o","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref5271","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/OGX.0b013e31815e8731","article-title":"Aspirin and reproductive outcomes","volume":"63","author":"James","year":"2008","journal-title":"Obstet Gynecol Surv"},{"key":"ref5141","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/(SICI)1099-1069(199609)14:3<119::AID-HON576>3.0.CO;2-Q","article-title":"Alpha-interferon and pregnancy in a patient with CML","volume":"14","author":"Lipton","year":"1996","journal-title":"Hematol Oncol"},{"key":"ref4651","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"key":"ref3471","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood-2008-09-180604","article-title":"Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia","volume":"114","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"ref3901","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"ref1171","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","volume":"28","author":"Hanfstein","year":"2014","journal-title":"Leukemia"},{"key":"ref3431","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s12185-014-1566-2","article-title":"Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study","volume":"99","author":"Baccarani","year":"2014","journal-title":"Int J Hematol"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1080\/10428194.2019.1607329","article-title":"Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts","volume":"60","author":"Xue","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref3021","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.leukres.2007.08.017","article-title":"A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts","volume":"32","author":"Burmeister","year":"2008","journal-title":"Leuk Res"},{"key":"ref3721","first-page":"295","article-title":"Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate","volume":"23","author":"Fugazza","year":"2004","journal-title":"J Exp Clin Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"ref2041","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2009.07646.x","article-title":"Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?","volume":"145","author":"Marin","year":"2009","journal-title":"Br J Haematol"},{"key":"ref4641","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00432-017-2385-7","article-title":"Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia","volume":"143","author":"Hoffmann","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref3161","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood-2002-07-2053","article-title":"Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority","volume":"101","author":"Bumm","year":"2003","journal-title":"Blood"},{"key":"ref3541","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series","volume":"176","author":"Bergeron","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"ref2461","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/sj.leu.2402494","article-title":"Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea","volume":"16","author":"Fadilah","year":"2002","journal-title":"Leukemia"},{"key":"ref1441","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol Oncol"},{"key":"ref2651","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2013.096776","article-title":"Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors","volume":"99","author":"Kim","year":"2014","journal-title":"Haematologica"},{"key":"ref1731","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2009.166","article-title":"Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters","volume":"23","author":"Davies","year":"2009","journal-title":"Leukemia"},{"key":"ref4311","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.suponc.2011.08.001","article-title":"Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner","volume":"10","author":"Cornelison","year":"2012","journal-title":"J Support Oncol"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref4811","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study","volume":"90","author":"Mori","year":"2015","journal-title":"Am J Hematol"},{"key":"ref1611","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clml.2016.02.002","article-title":"Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH Study","volume":"16","author":"Cortes","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref1781","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12032-018-1093-8","article-title":"Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase","volume":"35","author":"Tokuhira","year":"2018","journal-title":"Med Oncol"},{"key":"ref3341","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-019-0815-5","article-title":"Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper","volume":"12","author":"Soverini","year":"2019","journal-title":"J Hematol Oncol"},{"key":"ref5091","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2010-04-280206","article-title":"Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response","volume":"116","author":"Kuwabara","year":"2010","journal-title":"Blood"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/sj.leu.2403399","article-title":"Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia","volume":"18","author":"Terre","year":"2004","journal-title":"Leukemia"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref3481","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3324\/haematol.2018.188987","article-title":"Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia","volume":"104","author":"Hughes","year":"2019","journal-title":"Haematologica"},{"key":"ref2171","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00432-016-2321-2","article-title":"No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib","volume":"143","author":"Pfirrmann","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref2251","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3389\/fonc.2019.00665","article-title":"New approaches and treatment combinations for the management of chronic myeloid leukemia","volume":"9","author":"Westerweel","year":"2019","journal-title":"Front Oncol"},{"key":"ref3551","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4137\/CMO.S6413","article-title":"Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy","volume":"4","author":"Serpa","year":"2010","journal-title":"Clin Med Insights Oncol"},{"key":"ref4821","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"},{"key":"ref1451","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10741-020-09926-y","article-title":"Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib","volume":"25","author":"Casavecchia","year":"2020","journal-title":"Heart Fail Rev"},{"key":"ref4581","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s12185-018-2422-6","article-title":"Characteristics and outcome of chronic myeloid leukemia patients with E255K\/V BCR-ABL kinase domain mutations","volume":"107","author":"Naqvi","year":"2018","journal-title":"Int J Hematol"},{"key":"ref3511","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.leukres.2011.08.007","article-title":"Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia","volume":"36","author":"Orlandi","year":"2012","journal-title":"Leuk Res"},{"key":"ref5071","first-page":"1","article-title":"Pregnancy outcomes in chronic myeloid leukemia: a single center experience","volume":"5","author":"Madabhavi","year":"2019","journal-title":"J Glob Oncol"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2169\/internalmedicine.50.4481","article-title":"Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia","volume":"50","author":"Karimata","year":"2011","journal-title":"Intern Med"},{"key":"ref2761","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/cncr.20285","article-title":"Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia","volume":"100","author":"Quintas-Cardama","year":"2004","journal-title":"Cancer"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.12618","article-title":"Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia","volume":"164","author":"Deininger","year":"2014","journal-title":"Br J Haematol"},{"key":"ref111","first-page":"160","article-title":"Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia","volume":"9","author":"Kantarjian","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref1841","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2008-04-149948","article-title":"Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"ref2771","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"key":"ref2731","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"key":"ref3971","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref4371","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","article-title":"Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties","volume":"158","author":"Hegedus","year":"2009","journal-title":"Br J Pharmacol"},{"key":"ref2491","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/ejh.13167","article-title":"Successful pregnancies in patients with BCR-ABL-positive leukemias treated with interferon-alpha therapy during the tyrosine kinase inhibitors era","volume":"101","author":"Balsat","year":"2018","journal-title":"Eur J Haematol"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4103\/0019-509X.176741","article-title":"Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluation of molecular response of the a2b2 and a2b3 transcripts to Imatinib resistance in north Indian chronic myeloid leukemia patients","volume":"52","author":"Mir","year":"2015","journal-title":"Indian J Cancer"},{"key":"ref4621","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2015-08-660977","article-title":"Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients","volume":"127","author":"Deininger","year":"2016","journal-title":"Blood"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"ref3281","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/blood-2017-07-792143","article-title":"Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment","volume":"130","author":"Issa","year":"2017","journal-title":"Blood"},{"key":"ref3691","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1002\/cncr.24432","article-title":"Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure","volume":"115","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s12885-016-2635-0","article-title":"In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants","volume":"16","author":"Soverini","year":"2016","journal-title":"BMC Cancer"},{"key":"ref1991","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","article-title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","volume":"33","author":"Branford","year":"2019","journal-title":"Leukemia"},{"key":"ref2541","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1007\/s00277-015-2317-z","article-title":"Managing pregnancy in chronic myeloid leukaemia","volume":"94","author":"Palani","year":"2015","journal-title":"Ann Hematol"},{"key":"ref5201","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/ejh.13167","article-title":"Successful pregnancies in patients with BCR-ABL-positive leukemias treated with interferon-alpha therapy during the tyrosine kinase inhibitors era","volume":"101","author":"Balsat","year":"2018","journal-title":"Eur J Haematol"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref1511","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ajh.23408","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors","volume":"88","author":"Cortes","year":"2013","journal-title":"Am J Hematol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0950-3536(97)80003-0","article-title":"BCR-ABL gene variants","volume":"10","author":"Melo","year":"1997","journal-title":"Baillieres Clin Haematol"},{"key":"ref3231","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3324\/haematol.11064","article-title":"Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure","volume":"92","author":"Fabarius","year":"2007","journal-title":"Haematologica"},{"key":"ref2241","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol"},{"key":"ref4851","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","article-title":"Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study","volume":"144","author":"Ross","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"ref3051","article-title":"Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia [published online June 6, 2020]","author":"Pagani","journal-title":"Leuk Lymphoma"},{"key":"ref2331","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.24186","article-title":"The impact of dasatinib on pregnancy outcomes","volume":"90","author":"Cortes","year":"2015","journal-title":"Am J Hematol"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"key":"ref2181","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study","volume":"61","author":"Shah","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"ref2721","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"ref4301","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.3816\/CLM.2008.s.003","article-title":"Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"8","author":"Quint\u00e1s-Cardama","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"ref5151","first-page":"89","article-title":"Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report","volume":"21","author":"Baykal","year":"2000","journal-title":"Eur J Gynaecol Oncol"},{"key":"ref4931","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12943-018-0805-1","article-title":"Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia","volume":"17","author":"Massimino","year":"2018","journal-title":"Mol Cancer"},{"key":"ref5161","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/sj.leu.2402168","article-title":"Exposure to hydroxyurea during pregnancy: a case series","volume":"15","author":"Thauvin-Robinet","year":"2001","journal-title":"Leukemia"},{"key":"ref2621","doi-asserted-by":"crossref","first-page":"e2014028","DOI":"10.4084\/mjhid.2014.028","article-title":"Tyrosine kinase inhibitors and pregnancy","volume":"6","author":"Abruzzese","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref2271","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2141.2007.06542.x","article-title":"Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy","volume":"137","author":"Ramasamy","year":"2007","journal-title":"Br J Haematol"},{"key":"ref2111","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"},{"key":"ref3211","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-01-070045","article-title":"Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"110","author":"Jabbour","year":"2007","journal-title":"Blood"},{"key":"ref4071","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2003-06-2042","article-title":"Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses","volume":"102","author":"Marin","year":"2003","journal-title":"Blood"},{"key":"ref2281","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.leukres.2007.07.022","article-title":"Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases","volume":"32","author":"Breccia","year":"2008","journal-title":"Leuk Res"},{"key":"ref4571","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref1931","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/asheducation-2018.1.168","article-title":"Molecular monitoring in CML: how deep? How often? How should it influence therapy?","volume":"2018","author":"Shanmuganathan","year":"2018","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1080\/10428190600783551","article-title":"Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR\/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia","volume":"47","author":"Landstrom","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0301-472X(03)00176-0","article-title":"The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"31","author":"Feldman","year":"2003","journal-title":"Exp Hematol"},{"key":"ref4341","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.leukres.2018.02.013","article-title":"Efficacy and safety of nilotinib 300\u202fmg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the phase IIIb ENESTswift study","volume":"67","author":"Hiwase","year":"2018","journal-title":"Leuk Res"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/ajh.20859","article-title":"Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome","volume":"82","author":"Navarro","year":"2007","journal-title":"Am J Hematol"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ajh.22051","article-title":"Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia","volume":"86","author":"Tefferi","year":"2011","journal-title":"Am J Hematol"},{"key":"ref81","first-page":"2535","article-title":"Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment","volume":"24","author":"Douet-Guilbert","year":"2004","journal-title":"Anticancer Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"ref1221","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"ref3081","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2003-02-0371","article-title":"Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate","volume":"103","author":"O\u2019Dwyer","year":"2004","journal-title":"Blood"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(19)30027-4","article-title":"Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study","volume":"6","author":"Kizilors","year":"2019","journal-title":"Lancet Haematol"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2403077","article-title":"FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib","volume":"17","author":"Reinhold","year":"2003","journal-title":"Leukemia"},{"key":"ref1691","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/fcp.12007","article-title":"Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory","volume":"27","author":"Bouchet","year":"2013","journal-title":"Fundam Clin Pharmacol"},{"key":"ref3701","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/cncr.25533","article-title":"Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib","volume":"117","author":"Santos","year":"2011","journal-title":"Cancer"},{"key":"ref3371","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"ref4091","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","article-title":"Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance","volume":"114","author":"Verma","year":"2009","journal-title":"Blood"},{"key":"ref2121","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1038\/s41375-018-0264-0","article-title":"Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells","volume":"32","author":"Ross","year":"2018","journal-title":"Leukemia"},{"key":"ref4361","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression","volume":"68","author":"Mahon","year":"2008","journal-title":"Cancer Res"},{"key":"ref3661","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijcard.2019.04.051","article-title":"Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention","volume":"288","author":"Caocci","year":"2019","journal-title":"Int J Cardiol"},{"key":"ref3811","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"ref1771","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)","volume":"20","author":"Nicolini","year":"2006","journal-title":"Leukemia"},{"key":"ref4971","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"key":"ref4611","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"ref3581","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.leukres.2013.02.005","article-title":"Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors","volume":"37","author":"Berman","year":"2013","journal-title":"Leuk Res"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1182\/blood-2009-07-229864","article-title":"Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP","volume":"114","author":"Testoni","year":"2009","journal-title":"Blood"},{"key":"ref1411","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/ajh.24536","article-title":"Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"ref2051","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","article-title":"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib","volume":"114","author":"Press","year":"2009","journal-title":"Blood"},{"key":"ref3601","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1658-3876(09)50026-X","article-title":"Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia","volume":"2","author":"Aleem","year":"2009","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"ref3841","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref4321","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clml.2016.02.002","article-title":"Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH Study","volume":"16","author":"Cortes","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref4991","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.leukres.2007.07.022","article-title":"Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases","volume":"32","author":"Breccia","year":"2008","journal-title":"Leuk Res"},{"key":"ref3851","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","article-title":"Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies","volume":"121","author":"Neelakantan","year":"2013","journal-title":"Blood"},{"key":"ref2031","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2008.18.6999","article-title":"Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response","volume":"27","author":"Kantarjian","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref4271","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"ref1801","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"key":"ref3761","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"ref3401","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref4161","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10741-020-09926-y","article-title":"Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib","volume":"25","author":"Casavecchia","year":"2020","journal-title":"Heart Fail Rev"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N Engl J Med"},{"key":"ref3441","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.12618","article-title":"Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia","volume":"164","author":"Deininger","year":"2014","journal-title":"Br J Haematol"},{"key":"ref2471","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ijgo.2003.11.014","article-title":"Pregnancy in chronic myeloid leukemia patients treated with alpha interferon","volume":"85","author":"Al Bahar","year":"2004","journal-title":"Int J Gynaecol Obstet"},{"key":"ref1751","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"ref4241","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s00277-018-3413-7","article-title":"Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?","volume":"97","author":"Osorio","year":"2018","journal-title":"Ann Hematol"},{"key":"ref5301","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00404-008-0861-7","article-title":"Imatinib use during pregnancy and breast feeding: a case report and review of the literature","volume":"280","author":"Ali","year":"2009","journal-title":"Arch Gynecol Obstet"},{"key":"ref3361","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ajh.24943","article-title":"Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors","volume":"93","author":"Alhuraiji","year":"2018","journal-title":"Am J Hematol"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"ref5171","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/sj.leu.2402494","article-title":"Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea","volume":"16","author":"Fadilah","year":"2002","journal-title":"Leukemia"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.leukres.2013.02.005","article-title":"Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors","volume":"37","author":"Berman","year":"2013","journal-title":"Leuk Res"},{"key":"ref3491","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.24734","article-title":"Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion","volume":"116","author":"Porkka","year":"2010","journal-title":"Cancer"},{"key":"ref4401","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/fcp.12007","article-title":"Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory","volume":"27","author":"Bouchet","year":"2013","journal-title":"Fundam Clin Pharmacol"},{"key":"ref3101","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-015-0128-2","article-title":"Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis","volume":"8","author":"Wang","year":"2015","journal-title":"J Hematol Oncol"},{"key":"ref2391","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1080\/10428194.2018.1551533","article-title":"The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia","volume":"60","author":"Lasica","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref2401","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.21873\/invivo.11641","article-title":"Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib","volume":"33","author":"Stella","year":"2019","journal-title":"In Vivo"},{"key":"ref4281","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1185\/03007995.2010.533648","article-title":"Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/cncr.25533","article-title":"Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib","volume":"117","author":"Santos","year":"2011","journal-title":"Cancer"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3390\/jcm9051457","article-title":"Novel multiplex droplet digital PCR assays to mnitor minimal residual disease in chronic myeloid leukemia patients showing atypical BCR-ABL1 transcripts","volume":"9","author":"Petiti","year":"2020","journal-title":"J Clin Med"},{"key":"ref1831","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"ref2451","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/sj.leu.2402168","article-title":"Exposure to hydroxyurea during pregnancy: a case series","volume":"15","author":"Thauvin-Robinet","year":"2001","journal-title":"Leukemia"},{"key":"ref1881","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment of chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"ref3041","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4103\/0019-509X.176741","article-title":"Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluation of molecular response of the a2b2 and a2b3 transcripts to Imatinib resistance in north Indian chronic myeloid leukemia patients","volume":"52","author":"Mir","year":"2015","journal-title":"Indian J Cancer"},{"key":"ref3931","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref4981","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2141.2007.06542.x","article-title":"Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy","volume":"137","author":"Ramasamy","year":"2007","journal-title":"Br J Haematol"},{"key":"ref3781","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"key":"ref4721","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.51","article-title":"Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib","volume":"27","author":"Efficace","year":"2013","journal-title":"Leukemia"},{"key":"ref2831","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"ref1561","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"ref4231","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","article-title":"The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"key":"ref1721","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","article-title":"Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications","volume":"14","author":"Hiwase","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref2141","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","article-title":"Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study","volume":"144","author":"Ross","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref2961","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1080\/10428194.2019.1607329","article-title":"Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts","volume":"60","author":"Xue","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref5361","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2013.096776","article-title":"Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors","volume":"99","author":"Kim","year":"2014","journal-title":"Haematologica"},{"key":"ref2561","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/OGX.0b013e31815e8731","article-title":"Aspirin and reproductive outcomes","volume":"63","author":"James","year":"2008","journal-title":"Obstet Gynecol Surv"},{"key":"ref1591","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.3816\/CLM.2008.s.003","article-title":"Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"8","author":"Quint\u00e1s-Cardama","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"ref3091","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2015-05-646489","article-title":"Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"ref3681","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/cncr.20285","article-title":"Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia","volume":"100","author":"Quintas-Cardama","year":"2004","journal-title":"Cancer"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2009.021154","article-title":"Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group","volume":"95","author":"Cervantes","year":"2010","journal-title":"Haematologica"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.leukres.2007.08.017","article-title":"A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts","volume":"32","author":"Burmeister","year":"2008","journal-title":"Leuk Res"},{"key":"ref1461","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood-2008-09-180604","article-title":"Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia","volume":"114","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"ref3791","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","article-title":"Standardisation of molecular monitoring for chronic myeloid leukaemia","volume":"22","author":"Cross","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref2191","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","article-title":"Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial","volume":"7","author":"Kimura","year":"2020","journal-title":"Lancet Haematol"},{"key":"ref4451","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi","year":"2020","journal-title":"Cancer"},{"key":"ref1011","first-page":"295","article-title":"Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate","volume":"23","author":"Fugazza","year":"2004","journal-title":"J Exp Clin Cancer Res"},{"key":"ref2351","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/s41598-019-39134-0","article-title":"Imatinib treatments have long-term impact on placentation and embryo survival","volume":"9","author":"Salem","year":"2019","journal-title":"Sci Rep"},{"key":"ref2901","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1002\/cncr.31408","article-title":"The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia","volume":"124","author":"Ercaliskan","year":"2018","journal-title":"Cancer"},{"key":"ref3871","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"key":"ref1381","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","article-title":"Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"ref4151","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol Oncol"},{"key":"ref3121","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/cncr.25015","article-title":"Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy","volume":"116","author":"Verma","year":"2010","journal-title":"Cancer"},{"key":"ref4101","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","article-title":"TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets","volume":"125","author":"Yeung","year":"2015","journal-title":"Blood"},{"key":"ref2861","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","article-title":"The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"key":"ref3321","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s12885-016-2635-0","article-title":"In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants","volume":"16","author":"Soverini","year":"2016","journal-title":"BMC Cancer"},{"key":"ref2991","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.hemonc.2016.02.002","article-title":"Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring","volume":"10","author":"Crampe","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"ref1641","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"ref4021","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah","year":"2016","journal-title":"Am J Hematol"},{"key":"ref2151","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann Intern Med"},{"key":"ref2611","article-title":"Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and literature review","author":"Chelysheva","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3324\/haematol.2018.188987","article-title":"Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia","volume":"104","author":"Hughes","year":"2019","journal-title":"Haematologica"},{"key":"ref4501","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref4031","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"ref2851","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362","article-title":"The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease","volume":"92","author":"Bose","year":"1998","journal-title":"Blood"},{"key":"ref3801","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"key":"ref4671","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood.V86.8.3118.3118","article-title":"Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals","volume":"86","author":"Biernaux","year":"1995","journal-title":"Blood"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1002\/cncr.31408","article-title":"The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia","volume":"124","author":"Ercaliskan","year":"2018","journal-title":"Cancer"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood-2002-07-2053","article-title":"Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority","volume":"101","author":"Bumm","year":"2003","journal-title":"Blood"},{"key":"ref3941","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref4131","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-018-3507-2","article-title":"Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients","volume":"98","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Ann Hematol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/bjh.15453","article-title":"Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre","volume":"182","author":"Qin","year":"2018","journal-title":"Br J Haematol"},{"key":"ref3981","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/s41375-018-0055-7","article-title":"Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV","volume":"32","author":"Saussele","year":"2018","journal-title":"Leukemia"},{"key":"ref1351","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"ref2571","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/GCO.0b013e3282f10e33","article-title":"The use of low-molecular-weight heparins in pregnancy--how safe are they?","volume":"19","author":"Deruelle","year":"2007","journal-title":"Curr Opin Obstet Gynecol"},{"key":"ref4801","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref3061","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3390\/jcm9051457","article-title":"Novel multiplex droplet digital PCR assays to mnitor minimal residual disease in chronic myeloid leukemia patients showing atypical BCR-ABL1 transcripts","volume":"9","author":"Petiti","year":"2020","journal-title":"J Clin Med"},{"key":"ref5041","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.24186","article-title":"The impact of dasatinib on pregnancy outcomes","volume":"90","author":"Cortes","year":"2015","journal-title":"Am J Hematol"},{"key":"ref5401","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1038\/bcj.2014.60","article-title":"A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"4","author":"Seymour","year":"2014","journal-title":"Blood Cancer J"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref3381","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"key":"ref2821","first-page":"160","article-title":"Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia","volume":"9","author":"Kantarjian","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/10428199309047856","article-title":"The cytogenetic scenario of chronic myeloid leukemia","volume":"11","author":"Mitelman","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"ref3191","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/sj.leu.2403399","article-title":"Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia","volume":"18","author":"Terre","year":"2004","journal-title":"Leukemia"},{"key":"ref4211","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"ref2501","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref1581","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1185\/03007995.2011.649849","article-title":"Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia","volume":"28","author":"Yood","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"ref2581","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.jp.7211665","article-title":"Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk","volume":"27","author":"Russell","year":"2007","journal-title":"J Perinatol"},{"key":"ref2591","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00404-008-0861-7","article-title":"Imatinib use during pregnancy and breast feeding: a case report and review of the literature","volume":"280","author":"Ali","year":"2009","journal-title":"Arch Gynecol Obstet"},{"key":"ref2871","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","article-title":"Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib","volume":"99","author":"Hanfstein","year":"2014","journal-title":"Haematologica"},{"key":"ref2811","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood.V91.9.3357","article-title":"Highly sensitive fluorescence in situ hybridization method to detect double BCR\/ABL fusion and monitor response to therapy in chronic myeloid leukemia","volume":"91","author":"Dewald","year":"1998","journal-title":"Blood"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"ref1651","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression","volume":"68","author":"Mahon","year":"2008","journal-title":"Cancer Res"},{"key":"ref4761","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","article-title":"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib","volume":"114","author":"Press","year":"2009","journal-title":"Blood"},{"key":"ref3301","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/ajh.20859","article-title":"Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome","volume":"82","author":"Navarro","year":"2007","journal-title":"Am J Hematol"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","article-title":"Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies","volume":"121","author":"Neelakantan","year":"2013","journal-title":"Blood"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/cncr.11729","article-title":"Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase","volume":"98","author":"Medina","year":"2003","journal-title":"Cancer"},{"key":"ref2941","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1038\/bcj.2017.62","article-title":"Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia","volume":"7","author":"Gong","year":"2017","journal-title":"Blood Cancer J"},{"key":"ref4171","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"key":"ref5221","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/blood-2019-124430","article-title":"Pregnancy management in CML patients: to teat or not to treat? Report of 224 outcomes of the European Leukemia Net (ELN) Database","volume":"134","author":"Abruzzese","year":"2019","journal-title":"Blood"},{"key":"ref1671","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"ref3291","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2169\/internalmedicine.50.4481","article-title":"Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia","volume":"50","author":"Karimata","year":"2011","journal-title":"Intern Med"},{"key":"ref2081","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/j.ejca.2013.06.018","article-title":"Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)","volume":"49","author":"Thielen","year":"2013","journal-title":"Eur J Cancer"},{"key":"ref2791","first-page":"2535","article-title":"Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment","volume":"24","author":"Douet-Guilbert","year":"2004","journal-title":"Anticancer Res"},{"key":"ref4531","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"ref2071","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref3351","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ijlh.12616","article-title":"Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients","volume":"39","author":"Arun","year":"2017","journal-title":"Int J Lab Hematol"},{"key":"ref2441","first-page":"89","article-title":"Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report","volume":"21","author":"Baykal","year":"2000","journal-title":"Eur J Gynaecol Oncol"},{"key":"ref2211","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"ref2781","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/10428199309047856","article-title":"The cytogenetic scenario of chronic myeloid leukemia","volume":"11","author":"Mitelman","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"ref1471","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk Res"},{"key":"ref4591","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"key":"ref1701","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3324\/haematol.2011.056457","article-title":"Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib","volume":"97","author":"White","year":"2012","journal-title":"Haematologica"},{"key":"ref4521","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3324\/haematol.11369","article-title":"Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation","volume":"92","author":"Nicolini","year":"2007","journal-title":"Haematologica"},{"key":"ref4081","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"ref4891","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study","volume":"61","author":"Shah","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","article-title":"Standardisation of molecular monitoring for chronic myeloid leukaemia","volume":"22","author":"Cross","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref3861","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3324\/haematol.2013.090282","article-title":"Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months","volume":"98","author":"Nazha","year":"2013","journal-title":"Haematologica"},{"key":"ref4061","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"ref4381","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"ref2661","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/cncr.22901","article-title":"Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"key":"ref3741","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1182\/blood-2009-07-229864","article-title":"Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP","volume":"114","author":"Testoni","year":"2009","journal-title":"Blood"},{"key":"ref1311","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah","year":"2016","journal-title":"Am J Hematol"},{"key":"ref2881","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"ref3411","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"ref2341","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/1078155217692399","article-title":"Experience with dasatinib and nilotinib use in pregnancy","volume":"24","author":"Barkoulas","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"ref3331","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(19)30027-4","article-title":"Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study","volume":"6","author":"Kizilors","year":"2019","journal-title":"Lancet Haematol"},{"key":"ref4741","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2008.18.6999","article-title":"Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response","volume":"27","author":"Kantarjian","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref2951","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/bjh.15453","article-title":"Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre","volume":"182","author":"Qin","year":"2018","journal-title":"Br J Haematol"},{"key":"ref3531","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi","year":"2020","journal-title":"Cancer"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ajh.24774","article-title":"The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am J Hematol"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","article-title":"Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML","volume":"94","author":"Fabarius","year":"2015","journal-title":"Ann Hematol"},{"key":"ref1901","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"ref3521","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"ref1631","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.leukres.2018.02.013","article-title":"Efficacy and safety of nilotinib 300\u202fmg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the phase IIIb ENESTswift study","volume":"67","author":"Hiwase","year":"2018","journal-title":"Leuk Res"},{"key":"ref3501","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"ref4141","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"key":"ref3911","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"ref1871","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s12185-018-2422-6","article-title":"Characteristics and outcome of chronic myeloid leukemia patients with E255K\/V BCR-ABL kinase domain mutations","volume":"107","author":"Naqvi","year":"2018","journal-title":"Int J Hematol"},{"key":"ref1601","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.suponc.2011.08.001","article-title":"Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner","volume":"10","author":"Cornelison","year":"2012","journal-title":"J Support Oncol"},{"key":"ref4121","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/ajh.24536","article-title":"Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"key":"ref321","first-page":"433","article-title":"Comprehensive analysis of BCR\/ABL variants in chronic myeloid leukemia patients using multiplex RT-PCR","volume":"58","author":"Bennour","year":"2012","journal-title":"Clin Lab"},{"key":"ref4681","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1038\/bcj.2017.36","article-title":"Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia","volume":"7","author":"Togasaki","year":"2017","journal-title":"Blood Cancer J"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1038\/bcj.2017.62","article-title":"Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia","volume":"7","author":"Gong","year":"2017","journal-title":"Blood Cancer J"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/j.leukres.2009.05.010","article-title":"Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy","volume":"33","author":"Baldazzi","year":"2009","journal-title":"Leuk Res"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"ref1551","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref3461","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00432-017-2385-7","article-title":"Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia","volume":"143","author":"Hoffmann","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref2921","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance","volume":"114","author":"Verma","year":"2009","journal-title":"Blood"},{"key":"ref3561","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.51","article-title":"Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib","volume":"27","author":"Efficace","year":"2013","journal-title":"Leukemia"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3324\/haematol.2018.208801","article-title":"Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia","volume":"104","author":"Bidet","year":"2019","journal-title":"Haematologica"},{"key":"ref4261","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2015-05-646489","article-title":"Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series","volume":"176","author":"Bergeron","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"ref3181","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/cncr.11729","article-title":"Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase","volume":"98","author":"Medina","year":"2003","journal-title":"Cancer"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"ref3001","doi-asserted-by":"crossref","first-page":"969","DOI":"10.5858\/arpa.2014-0522-LE","article-title":"Standardized molecular monitoring for variant BCR-ABL1 transcripts in chronic myeloid leukemia","volume":"139","author":"Langabeer","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"ref3621","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"key":"ref4431","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","article-title":"Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications","volume":"14","author":"Hiwase","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/cncr.25015","article-title":"Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy","volume":"116","author":"Verma","year":"2010","journal-title":"Cancer"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/cncr.22936","article-title":"The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells","volume":"110","author":"Deininger","year":"2007","journal-title":"Cancer"},{"key":"ref3271","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1080\/10428194.2019.1636984","article-title":"Occurrence of chromosomal abnormalities in Philadelphia chromosome-negative metaphases in patients with chronic-phase chronic myeloid leukemia undergoing TKI treatments","volume":"60","author":"Sheng","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref4541","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"ref2931","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ijlh.12616","article-title":"Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients","volume":"39","author":"Arun","year":"2017","journal-title":"Int J Lab Hematol"},{"key":"ref3311","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3324\/haematol.2018.208801","article-title":"Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia","volume":"104","author":"Bidet","year":"2019","journal-title":"Haematologica"},{"key":"ref1821","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"ref3031","first-page":"433","article-title":"Comprehensive analysis of BCR\/ABL variants in chronic myeloid leukemia patients using multiplex RT-PCR","volume":"58","author":"Bennour","year":"2012","journal-title":"Clin Lab"},{"key":"ref4351","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.5858\/arpa.2013-0584-OA","article-title":"Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study","volume":"138","author":"Akard","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"ref3671","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12032-018-1093-8","article-title":"Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase","volume":"35","author":"Tokuhira","year":"2018","journal-title":"Med Oncol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"ref4951","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"key":"ref4411","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3324\/haematol.2011.056457","article-title":"Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib","volume":"97","author":"White","year":"2012","journal-title":"Haematologica"},{"key":"ref4421","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","article-title":"Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia","volume":"112","author":"Giannoudis","year":"2008","journal-title":"Blood"},{"key":"ref4731","first-page":"235","article-title":"The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia","volume":"91","author":"Wang","year":"2006","journal-title":"Haematologica"},{"key":"ref2631","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"key":"ref1421","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-018-3507-2","article-title":"Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients","volume":"98","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Ann Hematol"},{"key":"ref1971","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1038\/bcj.2017.36","article-title":"Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia","volume":"7","author":"Togasaki","year":"2017","journal-title":"Blood Cancer J"},{"key":"ref1571","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1185\/03007995.2010.533648","article-title":"Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"ref1941","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"key":"ref2091","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref1811","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3324\/haematol.11369","article-title":"Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation","volume":"92","author":"Nicolini","year":"2007","journal-title":"Haematologica"},{"key":"ref4911","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1002\/cncr.30885","article-title":"Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia","volume":"123","author":"Legros","year":"2017","journal-title":"Cancer"},{"key":"ref3251","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00277-013-1816-z","article-title":"Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy","volume":"92","author":"Wang","year":"2013","journal-title":"Ann Hematol"},{"key":"ref1681","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"ref1431","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"key":"ref3111","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"ref3571","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N Engl J Med"},{"key":"ref3451","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"ref3991","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2009.021154","article-title":"Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group","volume":"95","author":"Cervantes","year":"2010","journal-title":"Haematologica"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12185-019-02596-z","article-title":"Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia","volume":"109","author":"Sakurai","year":"2019","journal-title":"Int J Hematol"},{"key":"ref2531","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jjco\/hyh038","article-title":"Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature","volume":"34","author":"Ali","year":"2004","journal-title":"Jpn J Clin Oncol"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1002\/cncr.10490","article-title":"Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR\/ABL mRNA and undetectable BCR\/ABL protein may predict an indolent course","volume":"94","author":"Verstovsek","year":"2002","journal-title":"Cancer"},{"key":"ref1371","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"ref2311","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2014.10.002","article-title":"Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre","volume":"39","author":"Alizadeh","year":"2015","journal-title":"Leuk Res"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s12185-014-1566-2","article-title":"Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study","volume":"99","author":"Baccarani","year":"2014","journal-title":"Int J Hematol"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","article-title":"Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib","volume":"99","author":"Hanfstein","year":"2014","journal-title":"Haematologica"},{"key":"ref4861","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann Intern Med"},{"key":"ref5051","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/1078155217692399","article-title":"Experience with dasatinib and nilotinib use in pregnancy","volume":"24","author":"Barkoulas","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"ref2001","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/bloodadvances.2019000943","article-title":"Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia","volume":"4","author":"Adnan Awad","year":"2020","journal-title":"Blood Adv"},{"key":"ref1621","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00277-018-3295-8","article-title":"Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study","volume":"97","author":"Kim","year":"2018","journal-title":"Ann Hematol"},{"key":"ref3951","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"ref1861","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.24734","article-title":"Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion","volume":"116","author":"Porkka","year":"2010","journal-title":"Cancer"},{"key":"ref3071","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"ref3631","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ajh.22051","article-title":"Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia","volume":"86","author":"Tefferi","year":"2011","journal-title":"Am J Hematol"},{"key":"ref4051","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"ref1961","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"key":"ref3151","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ajh.24943","article-title":"Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors","volume":"93","author":"Alhuraiji","year":"2018","journal-title":"Am J Hematol"},{"key":"ref5021","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2014.10.002","article-title":"Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre","volume":"39","author":"Alizadeh","year":"2015","journal-title":"Leuk Res"},{"key":"ref2291","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00404-010-1501-6","article-title":"Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib","volume":"283","author":"Oweini","year":"2010","journal-title":"Arch Gynecol Obstet"},{"key":"ref5411","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.leukres.2018.10.002","article-title":"A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease","volume":"74","author":"Sweet","year":"2018","journal-title":"Leuk Res"},{"key":"ref4691","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"key":"ref3391","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment of chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"ref1711","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","article-title":"Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia","volume":"112","author":"Giannoudis","year":"2008","journal-title":"Blood"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362","article-title":"The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease","volume":"92","author":"Bose","year":"1998","journal-title":"Blood"},{"key":"ref5251","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1007\/s00277-015-2317-z","article-title":"Managing pregnancy in chronic myeloid leukaemia","volume":"94","author":"Palani","year":"2015","journal-title":"Ann Hematol"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.leukres.2011.08.007","article-title":"Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia","volume":"36","author":"Orlandi","year":"2012","journal-title":"Leuk Res"},{"key":"ref3711","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2403077","article-title":"FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib","volume":"17","author":"Reinhold","year":"2003","journal-title":"Leukemia"},{"key":"ref1401","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1016\/S2352-3026(16)30167-3","article-title":"Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial","volume":"3","author":"Cortes","year":"2016","journal-title":"Lancet Haematol"},{"key":"ref5121","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1600-0609.1996.tb00497.x","article-title":"Two cases of CML treated with alpha-interferon during second and third trimester of pregnancy with analysis of the drug in the new-born immediately postpartum","volume":"57","author":"Haggstrom","year":"1996","journal-title":"Eur J Haematol"},{"key":"ref4391","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"ref5211","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref4881","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref5001","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00404-010-1501-6","article-title":"Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib","volume":"283","author":"Oweini","year":"2010","journal-title":"Arch Gynecol Obstet"},{"key":"ref3261","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cancergen.2019.07.008","article-title":"Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors","volume":"238","author":"Ni","year":"2019","journal-title":"Cancer Genet"},{"key":"ref271","first-page":"458716","article-title":"Chronic myeloid leukemia with e19a2 BCR-ABL1 transcripts and marked thrombocytosis: the role of molecular monitoring","volume":"2012","author":"Langabeer","year":"2012","journal-title":"Case Rep Hematol"},{"key":"ref3141","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"ref4601","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"key":"ref1301","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref4251","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"ref2361","first-page":"1","article-title":"Pregnancy outcomes in chronic myeloid leukemia: a single center experience","volume":"5","author":"Madabhavi","year":"2019","journal-title":"J Glob Oncol"},{"key":"ref5101","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1080\/10428194.2018.1551533","article-title":"The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia","volume":"60","author":"Lasica","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref2511","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/blood-2019-124430","article-title":"Pregnancy management in CML patients: to teat or not to treat? Report of 224 outcomes of the European Leukemia Net (ELN) Database","volume":"134","author":"Abruzzese","year":"2019","journal-title":"Blood"},{"key":"ref5341","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"key":"ref3641","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"ref1501","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-015-0128-2","article-title":"Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis","volume":"8","author":"Wang","year":"2015","journal-title":"J Hematol Oncol"},{"key":"ref1251","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.2011.36.0693","article-title":"Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?","volume":"29","author":"Jabbour","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/cncr.25678","article-title":"Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond","volume":"117","author":"Lima","year":"2011","journal-title":"Cancer"},{"key":"ref4011","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref2551","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/trf.14448","article-title":"Management of chronic myeloid leukemia in the setting of pregnancy: when is leukocytapheresis appropriate? A case report and review of the literature","volume":"58","author":"Staley","year":"2018","journal-title":"Transfusion"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1185\/03007995.2014.904281","article-title":"Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase","volume":"30","author":"Gu\u00e9rin","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"ref4961","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3389\/fonc.2019.00665","article-title":"New approaches and treatment combinations for the management of chronic myeloid leukemia","volume":"9","author":"Westerweel","year":"2019","journal-title":"Front Oncol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.hemonc.2016.02.002","article-title":"Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring","volume":"10","author":"Crampe","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/blood-2017-07-792143","article-title":"Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment","volume":"130","author":"Issa","year":"2017","journal-title":"Blood"},{"key":"ref2201","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1002\/cncr.30885","article-title":"Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia","volume":"123","author":"Legros","year":"2017","journal-title":"Cancer"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/10\/article-p1385.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/18\/10\/article-p1385.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T05:33:14Z","timestamp":1698211994000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/10\/article-p1385.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":534,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2020.0047","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}